[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394964":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":31,"locations":37,"responsibleParty":240,"collaborators":24,"id":242,"slug":24,"hasResults":243,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":24,"eligibilityCriteria":247,"healthyVolunteers":243,"sex":248,"minAge":249,"maxAge":24,"enrollmentInfo":250,"targetDuration":24,"studyType":253,"phases":254,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":283},{"fullName":5,"class":6},"Cabaletta Bio","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DSG3-CAART","EXPERIMENTAL","Single or multiple intravenous infusion(s) of DSG3-CAART at varying dose levels.\n\nThis study is now closed to enrollment.",[13],"Biological: DSG3-CAART",{"label":15,"type":10,"description":16,"interventionNames":17},"CABA-201","Infusion of CABA-201 with or without cyclophosphamide and fludarabine preconditioning, or with or without cyclophosphamide preconditioning.\n\nThis sub-study is open to enrollment.",[18],"Biological: CABA-201",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Intravenous infusions of DSG3-CAART alone at different doses and different fractionations, with or without intravenous immunoglobulin, cyclophosphamide, and\u002For fludarabine.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Single intravenous infusion of CABA-201 at escalating doses, with or without preconditioning.",[15],[29],{"name":5,"affiliation":5,"role":30},"STUDY_CHAIR",[32],{"name":5,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+1 267 759 3100","4444","clinicaltrials@cabalettabio.com",[38,59,75,92,109,126,146,156,169,179,196,213,229],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Stanford University, Dept. of Dermatology","RECRUITING","Redwood City","California","94063","United States",{"type":46,"coordinates":47},"Point",[48,49],-122.23635,37.48522,{"lat":49,"lon":48},[52,56],{"name":53,"role":33,"phone":54,"phoneExt":24,"email":55},"Kunju Sridhar, PhD","650-721-4902","kunju@stanford.edu",{"name":57,"role":58,"phone":24,"phoneExt":24,"email":24},"M. Peter Marinkovich, MD","PRINCIPAL_INVESTIGATOR",{"facility":60,"status":40,"city":61,"state":42,"zip":62,"country":44,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"UC Davis, Dept. of Dermatology","Sacramento","95816",{"type":46,"coordinates":64},[65,66],-121.4944,38.58157,{"lat":66,"lon":65},[69,73],{"name":70,"role":33,"phone":71,"phoneExt":24,"email":72},"Lauren Downing","916-551-2635","ladowning@ucdavis.edu",{"name":74,"role":58,"phone":24,"phoneExt":24,"email":24},"Mehrdad Abedi, MD",{"facility":76,"status":40,"city":77,"state":78,"zip":79,"country":44,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Yale University","New Haven","Connecticut","06520",{"type":46,"coordinates":81},[82,83],-72.92816,41.30815,{"lat":83,"lon":82},[86,90],{"name":87,"role":33,"phone":88,"phoneExt":24,"email":89},"Andrea DeClement","475-255-8031","andrea.declement@yale.edu",{"name":91,"role":58,"phone":24,"phoneExt":24,"email":24},"Mary Tomayko, MD, PhD",{"facility":93,"status":40,"city":94,"state":95,"zip":96,"country":44,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Northwestern University","Chicago","Illinois","60611",{"type":46,"coordinates":98},[99,100],-87.65005,41.85003,{"lat":100,"lon":99},[103,107],{"name":104,"role":33,"phone":105,"phoneExt":24,"email":106},"NU Dermatology CTU","312-503-5944","NUderm-research@northwestern.edu",{"name":108,"role":58,"phone":24,"phoneExt":24,"email":24},"Alan Zhou, MD",{"facility":110,"status":40,"city":111,"state":112,"zip":113,"country":44,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"University of Iowa","Iowa City","Iowa","52242",{"type":46,"coordinates":115},[116,117],-91.53017,41.66113,{"lat":117,"lon":116},[120,124],{"name":121,"role":33,"phone":122,"phoneExt":24,"email":123},"Amanda Howell","319-384-6843","amanda-steahr@uiowa.edu",{"name":125,"role":58,"phone":24,"phoneExt":24,"email":24},"Emma Killoran, MD",{"facility":127,"status":40,"city":128,"state":129,"zip":130,"country":44,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":46,"coordinates":132},[133,134],-71.05977,42.35843,{"lat":134,"lon":133},[137,141,144],{"name":138,"role":33,"phone":139,"phoneExt":24,"email":140},"Sydney Chase","617-525-7638","schase@bwh.harvard.edu",{"name":142,"role":33,"phone":24,"phoneExt":24,"email":143},"Rebecca Wenzel-Rideout","rwenzel-rideout@bwh.harvard.edu",{"name":145,"role":58,"phone":24,"phoneExt":24,"email":24},"Arash Mostaghimi, MD, MPH, FAAD",{"facility":147,"status":148,"city":149,"state":149,"zip":150,"country":44,"cosmosGeoPoint":151,"geoPoint":155,"contacts":24},"Mount Sinai - Icahn School of Medicine","WITHDRAWN","New York","10029",{"type":46,"coordinates":152},[153,154],-74.00597,40.71427,{"lat":154,"lon":153},{"facility":157,"status":40,"city":149,"state":149,"zip":158,"country":44,"cosmosGeoPoint":159,"geoPoint":161,"contacts":162},"Columbia University","10032",{"type":46,"coordinates":160},[153,154],{"lat":154,"lon":153},[163,167],{"name":164,"role":33,"phone":165,"phoneExt":24,"email":166},"Hei Ton \"Jason\" Chan","646-317-6360","htc2110@cumc.columbia.edu",{"name":168,"role":58,"phone":24,"phoneExt":24,"email":24},"Alexandra Coromilas, MD",{"facility":170,"status":148,"city":171,"state":172,"zip":173,"country":44,"cosmosGeoPoint":174,"geoPoint":178,"contacts":24},"University of North Carolina, Department of Dermatology","Chapel Hill","North Carolina","27516",{"type":46,"coordinates":175},[176,177],-79.05584,35.9132,{"lat":177,"lon":176},{"facility":180,"status":40,"city":181,"state":182,"zip":183,"country":44,"cosmosGeoPoint":184,"geoPoint":188,"contacts":189},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":46,"coordinates":185},[186,187],-75.16362,39.95238,{"lat":187,"lon":186},[190,194],{"name":191,"role":33,"phone":192,"phoneExt":24,"email":193},"Marie DeMarco","215-349-5699","marie.demarco@pennmedicine.upenn.edu",{"name":195,"role":58,"phone":24,"phoneExt":24,"email":24},"David Porter, MD",{"facility":197,"status":40,"city":198,"state":199,"zip":200,"country":44,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"UT Southwestern Medical Center, Dept. of Dermatology","Dallas","Texas","75235",{"type":46,"coordinates":202},[203,204],-96.80667,32.78306,{"lat":204,"lon":203},[207,211],{"name":208,"role":33,"phone":209,"phoneExt":24,"email":210},"Aleuna Lee","214-645-8968","aleuna.lee@utsouthwestern.edu",{"name":212,"role":58,"phone":24,"phoneExt":24,"email":24},"Arturo Dominguez, MD",{"facility":214,"status":40,"city":215,"state":199,"zip":216,"country":44,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"MD Anderson Texas Medical Center","Houston","77030",{"type":46,"coordinates":218},[219,220],-95.36327,29.76328,{"lat":220,"lon":219},[223,227],{"name":224,"role":33,"phone":225,"phoneExt":24,"email":226},"Alda Ashu","713-792-1280","abmiraso@mdanderson.org",{"name":228,"role":58,"phone":24,"phoneExt":24,"email":24},"Omar Pacha, MD",{"facility":230,"status":231,"city":232,"state":233,"zip":234,"country":44,"cosmosGeoPoint":235,"geoPoint":239,"contacts":24},"University of Washington","COMPLETED","Seattle","Washington","98109",{"type":46,"coordinates":236},[237,238],-122.33207,47.60621,{"lat":238,"lon":237},{"type":241,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100394964",false,"NCT04422912","A Phase 1\u002F2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)","A Phase 1\u002F2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris","Inclusion Criteria for DSG3-CAART: Closed to enrollment\n\n* Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n* mPV inadequately managed by at least one standard immunosuppressive therapies\n* Active mPV at screening\n* Anti-DSG3 antibody ELISA positive at screening\n\nInclusion Criteria for CABA-201 sub-study: Open to enrollment\n\n* Age ≥18\n* Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3 ELISA, IIF, and\u002For DIF\n* PV inadequately managed by at least one standard immunosuppressive therapy\n* Active PV at screening\n* DSG3 ELISA positive at screening\n\nExclusion Criteria:\n\n* Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease\n* Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased\n* Prednisone \\> 0.25mg\u002Fkg\u002Fday\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Investigational treatment in last 3 months\n\nExclusion Criteria for CABA-201 sub-study\n\n* Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skin cancer) or malignancy diagnosed within the previous 5 years\n* Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 months unless anti-DSG3 antibody titers have recently increased or PV symptoms have recently worsened\n* Prednisone \\> 0.25mg\u002Fkg\u002Fday\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Treatment with any investigational agent within 4 weeks or 5 half-lives, whichever is longer.","ALL","18 Years",{"count":251,"type":252},40,"ESTIMATED","INTERVENTIONAL",[255,256],"PHASE1","PHASE2","A phase 1\u002F2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \\[DSG3-CAART\\] or CD19-specific Chimeric Antigen Receptor T cells \\[CABA-201\\]) in subjects with active, pemphigus vulgaris",[259],"Pemphigus Vulgaris",[261,259,262,263,264,265,266,267,268,269,270,15,271,272,273],"Pemphigus","CAAR-T Therapy","CAR-T Therapy","Desmoglein 3","Cell Therapy","Autoimmune Disease","Autoimmunity","Skin Diseases, Vesiculobullous","Immunotherapy, Adoptive","Immune System Diseases","Anti-CD19 CAR-T therapy","Resecabtagene Autoleucel","Rese-cel","2026-05-28",{"date":276,"type":277},"2026-05-29","ACTUAL",{"date":279,"type":277},"2020-09-29",{"date":281,"type":252},"2029-01",{"name":5,"class":6},13]